Skip to main navigation Skip to search Skip to main content

Linezolid induced toxic optic neuropathy in drug resistant tuberculosis-A case series

Research output: Contribution to journalArticlepeer-review

Abstract

In developing countries like India, Linezolid is widely used for the treatment of Multi drug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). Long-term administration of Linezolid is reported to cause toxic optic neuropathy causing bilateral, progressive visual loss in patients. We report case details of three patients on anti-tubercular therapy presented to us with sudden, progressive, painless blurring of vision of both eyes the cause of which was confirmed to be toxic optic neuropathy due to linezolid. Subsequently, cessation of the drug resulted in complete visual recovery in two patients whereas one patient had minimal visual improvement due to secondary optic atrophy. Clinicians and health care workers need to be aware of sight threatening complications of Linezolid.

Original languageEnglish
Pages (from-to)S5-S9
JournalIndian Journal of Tuberculosis
Volume71
DOIs
Publication statusAccepted/In press - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Linezolid induced toxic optic neuropathy in drug resistant tuberculosis-A case series'. Together they form a unique fingerprint.

Cite this